Nxera Pharma / Sosei Heptares

Nxera Pharma is a biopharmaceutical company based in Tokyo, Japan, dedicated to developing specialty medicines for unmet medical needs. Founded in 1990 as Sosei Group, the company has grown into a technology-driven entity listed on the Tokyo Stock Exchange. With a workforce of over 350 employees across Japan, the UK, Switzerland, and South Korea, Nxera Pharma focuses on accelerating the development of life-changing medicines through its proprietary NxWave™ discovery platform. The company has a robust pipeline with over 30 active programs in various stages of development, targeting areas such as neurology, gastrointestinal diseases, immunology, metabolic diseases, and rare diseases. Nxera Pharma is committed to building a new-generation commercial infrastructure in Japan and pursuing partnerships to enhance its innovative treatments. Its lead product, PIVLAZ, is currently in multiple phases of development, showcasing the company's dedication to addressing significant healthcare challenges.